UBS Group’s Apollo Endosurgery APEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-223
| Closed | -$2.21K | – | 10401 |
|
|
2023
Q1 | $2.21K | Sell |
223
-35,105
| -99% | -$348K | ﹤0.01% | 8551 |
|
|
2022
Q4 | $352K | Buy |
35,328
+31,773
| +894% | +$237K | ﹤0.01% | 4991 |
|
|
2022
Q3 | $20K | Buy |
3,555
+526
| +17% | +$2.92K | ﹤0.01% | 7438 |
|
|
2022
Q2 | $11K | Buy |
3,029
+1,378
| +83% | +$6.51K | ﹤0.01% | 7906 |
|
|
2022
Q1 | $10K | Sell |
1,651
-137
| -8% | -$835 | ﹤0.01% | 8484 |
|
|
2021
Q4 | $15K | Buy |
1,788
+1,392
| +352% | +$12.2K | ﹤0.01% | 8288 |
|
|
2021
Q3 | $3K | Sell |
396
-3,332
| -89% | -$28.6K | ﹤0.01% | 8887 |
|
|
2021
Q2 | $30K | Buy |
3,728
+2,432
| +188% | +$16.7K | ﹤0.01% | 6953 |
|
|
2021
Q1 | $7K | Sell |
1,296
-2,670
| -67% | -$13.2K | ﹤0.01% | 8181 |
|
|
2020
Q4 | $13K | Buy |
3,966
+1,517
| +62% | +$4K | ﹤0.01% | 7307 |
|
|
2020
Q3 | $4K | Buy |
2,449
+1,454
| +146% | +$2.19K | ﹤0.01% | 7469 |
|
|
2020
Q2 | $2K | Sell |
995
-4,160
| -81% | -$8.26K | ﹤0.01% | 7692 |
|
|
2020
Q1 | $10K | Buy |
5,155
+4,611
| +848% | +$12.1K | ﹤0.01% | 6951 |
|
|
2019
Q4 | $2K | Sell |
544
-600
| -52% | -$1.74K | ﹤0.01% | 7880 |
|
|
2019
Q3 | $4K | Sell |
1,144
-37
| -3% | -$117 | ﹤0.01% | 7583 |
|
|
2019
Q2 | $4K | Sell |
1,181
-184
| -13% | -$654 | ﹤0.01% | 7478 |
|
|
2019
Q1 | $5K | Sell |
1,365
-3,220
| -70% | -$11.3K | ﹤0.01% | 7203 |
|
|
2018
Q4 | $16K | Sell |
4,585
-2,469
| -35% | -$12.2K | ﹤0.01% | 6964 |
|
|
2018
Q3 | $51K | Buy |
7,054
+3,398
| +93% | +$26.4K | ﹤0.01% | 6154 |
|
|
2018
Q2 | $26K | Buy |
3,656
+1,982
| +118% | +$12.3K | ﹤0.01% | 6516 |
|
|
2018
Q1 | $10K | Buy |
+1,674
| New | +$10.5K | ﹤0.01% | 6894 |
|
|
2017
Q2 | – | Sell |
-1,014
| Closed | -$13K | – | 8095 |
|
|
2017
Q1 | $13K | Sell |
1,014
-2,490
| -71% | -$31.7K | ﹤0.01% | 6472 |
|
|
2016
Q4 | $43K | Buy |
+3,504
| New | +$53.4K | ﹤0.01% | 5948 |
|
|
2016
Q3 | – | Sell |
-531
| Closed | -$6K | – | 8023 |
|
|
2016
Q2 | $6K | Buy |
+531
| New | +$7.98K | ﹤0.01% | 7063 |
|
|
2015
Q1 | – | Sell |
-7
| Closed | -$2K | – | 9555 |
|
|
2014
Q4 | $2K | Buy |
+7
| New | +$1.56K | ﹤0.01% | 9441 |
|
|
2014
Q3 | – | Sell |
-11
| Closed | -$3K | – | 10886 |
|
|
2014
Q2 | $3K | Buy |
+11
| New | +$3.49K | ﹤0.01% | 9879 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 10945 |
|
|
2013
Q4 | – | Sell |
-51
| Closed | -$18.7K | – | 10872 |
|
|
2013
Q3 | $22K | Buy |
51
+18
| +55% | +$7.88K | ﹤0.01% | 7955 |
|
|
2013
Q2 | $11K | Hold |
33
| – | – | ﹤0.01% | 8558 |
|
UBS Group's APEN Position: Q2 2023 in Review
UBS Group sold out of Apollo Endosurgery (APEN) in Q2 2023, closing a stake of 223 shares — an estimated $2.21K sold.
UBS Group first reported a position in APEN in Q2 2013 and held it in 28 quarters. The position peaked at $352K in Q4 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.
- UBS Group reported no remaining Apollo Endosurgery position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 223 Apollo Endosurgery shares in Q2 2023, an estimated $2.21K.
- UBS Group first reported a position in Apollo Endosurgery in Q2 2013 and held it in 28 quarters.
- UBS Group's Apollo Endosurgery position peaked at $352K in Q4 2022.
- 0 funds tracked by Wall St. Rank held Apollo Endosurgery as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.